Semin Liver Dis 2015; 35(01): 043-054
DOI: 10.1055/s-0034-1397348
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Circulating microRNAs: Emerging Biomarkers of Liver Disease

Marco Arrese
1   Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
,
Akiko Eguchi
2   Department of Pediatric Gastroenterology, Rady Children's Hospital, University of California San Diego, California
,
Ariel E. Feldstein
2   Department of Pediatric Gastroenterology, Rady Children's Hospital, University of California San Diego, California
› Author Affiliations
Further Information

Publication History

Publication Date:
29 January 2015 (online)

Abstract

Development of reliable, noninvasive biomarkers that allow for diagnosis, risk stratification, and monitoring of disease changes over time or in response to specific therapies represents a key priority in the field of hepatology. Recent evidence has uncovered the role of microRNAs as potential ideal biomarkers of liver injury in various acute and chronic liver diseases. These small noncoding RNAs are released to the extracellular space in a stress-specific manner and are remarkably stable in most bodily fluids including blood, where they circulate in specific compartments including extracellular vesicles and protein complexes. In this review, the authors provide a concise overview of available information on the emerging role of quantitation of circulating microRNAs in different liver diseases and their use as biomarkers for both diagnosis and prognosis assessment. Additionally, several key issues that still need to be addressed for microRNAs to become useful tools in daily clinical practice are critically reviewed.

 
  • References

  • 1 De Guire V, Robitaille R, Tétreault N , et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem 2013; 46 (10–11) 846-860
  • 2 Srivastava SK, Bhardwaj A, Leavesley SJ, Grizzle WE, Singh S, Singh AP. MicroRNAs as potential clinical biomarkers: emerging approaches for their detection. Biotech Histochem 2013; 88 (7) 373-387
  • 3 Chen X, Ba Y, Ma L , et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18 (10) 997-1006
  • 4 Mitchell PS, Parkin RK, Kroh EM , et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105 (30) 10513-10518
  • 5 Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10 (9) 542-552
  • 6 Hornby RJ, Starkey Lewis P, Dear J, Goldring C, Park BK. MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. Expert Rev Clin Pharmacol 2014; 7 (3) 349-362
  • 7 Bala S, Petrasek J, Mundkur S , et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012; 56 (5) 1946-1957
  • 8 Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: fad or future of liver disease. World J Gastroenterol 2011; 17 (20) 2536-2542
  • 9 Pogribny IP, Beland FA. Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease. Expert Opin Drug Metab Toxicol 2013; 9 (6) 713-724
  • 10 Chen Y, Verfaillie CM. MicroRNAs: the fine modulators of liver development and function. Liver Int 2014; 34 (7) 976-990
  • 11 Hsu SH, Ghoshal K. MicroRNAs in liver health and disease. Curr Pathobiol Rep 2013; 1 (1) 53-62
  • 12 Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Ohno M, Koike K. MicroRNAs and liver function. Minerva Gastroenterol Dietol 2013; 59 (2) 187-203
  • 13 Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res 2013; 100 (1) 7-18
  • 14 Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002; 48 (10) 1647-1653
  • 15 Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. Circulating miRNAs: cell-cell communication function?. Front Genet 2013; 4: 119
  • 16 Chen X, Liang H, Zhang J, Zen K, Zhang CY. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 2012; 3 (1) 28-37
  • 17 Rani S. MicroRNA profiling of exosomes isolated from biofluids and conditioned media. Methods Mol Biol 2014; 1182: 131-144
  • 18 Lemoinne S, Thabut D, Housset C , et al. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol 2014; 11 (6) 350-361
  • 19 György B, Szabó TG, Pásztói M , et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68 (16) 2667-2688
  • 20 Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200 (4) 373-383
  • 21 Eguchi A, Dowdy SF. siRNA delivery using peptide transduction domains. Trends Pharmacol Sci 2009; 30 (7) 341-345
  • 22 Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13 (4) 423-433
  • 23 Arroyo JD, Chevillet JR, Kroh EM , et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108 (12) 5003-5008
  • 24 Pirola CJ, Fernández Gianotti T, Castaño GO , et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2014;
  • 25 Povero D, Eguchi A, Niesman IR , et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal 2013; 6 (296) ra88
  • 26 Esau C, Davis S, Murray SF , et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3 (2) 87-98
  • 27 Tsai WC, Hsu SD, Hsu CS , et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122 (8) 2884-2897
  • 28 Wang K, Zhang S, Marzolf B , et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106 (11) 4402-4407
  • 29 Köberle V, Pleli T, Schmithals C , et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS ONE 2013; 8 (9) e75184
  • 30 Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 2014; 3 : 10.3402/jev.v3.23743
  • 31 Wang Z, Yang B. MicroRNA Expression Detection Methods. Heidelberg, Germany: Springer; 2010
  • 32 Ramaiah SK. Preclinical safety assessment: current gaps, challenges, and approaches in identifying translatable biomarkers of drug-induced liver injury. Clin Lab Med 2011; 31 (1) 161-172
  • 33 Aithal GP, Guha N, Fallowfield J, Castera L, Jackson AP. Biomarkers in liver disease: emerging methods and potential applications. Int J Hepatol 2012; 2012: 437508
  • 34 Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC ; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47 (4) 1363-1370
  • 35 Mofrad P, Contos MJ, Haque M , et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37 (6) 1286-1292
  • 36 Molleston JP, Schwimmer JB, Yates KP , et al; NASH Clinical Research Network. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164 (4) 707-713.e3
  • 37 Hong H, Tong W. Emerging efforts for discovering new biomarkers of liver disease and hepatotoxicity. Biomarkers Med 2014; 8 (2) 143-146
  • 38 Starkey Lewis PJ, Merz M, Couttet P , et al. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther 2012; 92 (3) 291-293
  • 39 Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014; 146 (4) 914-928
  • 40 Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014; 34 (2) 115-122
  • 41 Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34 (2) 123-133
  • 42 Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol 2014; 14 (4) 286-292
  • 43 Su YW, Chen X, Jiang ZZ , et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS ONE 2012; 7 (5) e37395
  • 44 Starkey Lewis PJ, Dear J, Platt V , et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54 (5) 1767-1776
  • 45 Antoine DJ, Dear JW, Lewis PS , et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013; 58 (2) 777-787
  • 46 Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM ; Acute Liver Failure Study Group. Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. J Med Virol 2014; 86 (9) 1507-1514
  • 47 Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology 2012; 55 (5) 1640-1642 , author reply 1642–1643
  • 48 Ward J, Kanchagar C, Veksler-Lublinsky I , et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci U S A 2014; 111 (33) 12169-12174
  • 49 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16) 1221-1231
  • 50 Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59 (6) 2188-2195
  • 51 Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46 (2) 582-589
  • 52 Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets 2013; 17 (7) 773-779
  • 53 Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol 2014; 34 (6) 726-732
  • 54 Yamada H, Suzuki K, Ichino N , et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013; 424: 99-103
  • 55 Longchamps RJ, Abey SK, Martino AC, Henderson WA. Letter: gender-associated cell-free microRNA profiles in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 39 (9) 997-998
  • 56 Vincent R, Sanyal A. Recent advances in understanding of NASH: MicroRNAs as both biochemical markers and players. Curr Pathobiol Rep 2014; 2: 109-116
  • 57 Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013; 5 (9) 479-486
  • 58 Singaravelu R, Russell RS, Tyrrell DL, Pezacki JP. Hepatitis C virus and microRNAs: miRed in a host of possibilities. Curr Opin Virol 2014; 7: 1-10
  • 59 Randall G, Panis M, Cooper JD , et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007; 104 (31) 12884-12889
  • 60 Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Das S. Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 2013; 3: 1555
  • 61 Bihrer V, Friedrich-Rust M, Kronenberger B , et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106 (9) 1663-1669
  • 62 van der Meer AJ, Farid WR, Sonneveld MJ , et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013; 20 (3) 158-166
  • 63 Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB. Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 2013; 58 (3) 863-871
  • 64 Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer 2012; 3: 19-31
  • 65 Thirion M, Ochiya T. Roles of microRNAs in the hepatitis B virus infection and related diseases. Viruses 2013; 5 (11) 2690-2703
  • 66 Wei YF, Cui GY, Ye P, Chen JN, Diao HY. MicroRNAs may solve the mystery of chronic hepatitis B virus infection. World J Gastroenterol 2013; 19 (30) 4867-4876
  • 67 Zhang X, Hou J, Lu M. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet 2013; 4: 202
  • 68 Novellino L, Rossi RL, Bonino F , et al. Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. PLoS ONE 2012; 7 (3) e31952
  • 69 Ji F, Yang B, Peng X, Ding H, You H, Tien P. Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 2011; 18 (7) e242-e251
  • 70 Zhang H, Li QY, Guo ZZ , et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 2012; 18 (37) 5188-5196
  • 71 Arataki K, Hayes CN, Akamatsu S , et al. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol 2013; 85 (5) 789-798
  • 72 Waidmann O, Bihrer V, Pleli T , et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19 (2) e58-e65
  • 73 Winther TN, Heiberg IL, Bang-Berthelsen CH, Pociot F, Hogh B. Hepatitis B surface antigen quantity positively correlates with plasma levels of microRNAs differentially expressed in immunological phases of chronic hepatitis B in children. PLoS ONE 2013; 8 (11) e80384
  • 74 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379 (9822) 1245-1255
  • 75 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014; 12 (3) 375-382
  • 76 Forner A, Bruix J. Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol 2012; 13 (8) 750-751
  • 77 Li X, Yang W, Lou L, Chen Y, Wu S, Ding G. microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci 2014; 59 (6) 1099-1107
  • 78 Otsuka M, Kishikawa T, Yoshikawa T , et al. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol 2014; 49 (2) 173-184
  • 79 Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T. The role of microRNAs in human liver cancers. Semin Oncol 2011; 38 (6) 752-763
  • 80 Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE 2011; 6 (12) e28486
  • 81 Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45 (4) 355-360
  • 82 Zhang ZQ, Meng H, Wang N , et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014; 9: 135
  • 83 Liu AM, Yao TJ, Wang W , et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2 (2) e000825
  • 84 Li LM, Hu ZB, Zhou ZX , et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70 (23) 9798-9807
  • 85 Zhou J, Yu L, Gao X , et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29 (36) 4781-4788
  • 86 Yang Y, Zhu R. Diagnostic value of circulating microRNAs for hepatocellular carcinoma. Mol Biol Rep 2014; 41 (10) 6919-6929
  • 87 Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014; 2014: 864894
  • 88 Köberle V, Kronenberger B, Pleli T , et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49 (16) 3442-3449
  • 89 Marin JJ, Bujanda L, Banales JM. MicroRNAs and cholestatic liver diseases. Curr Opin Gastroenterol 2014; 30 (3) 303-309
  • 90 Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012; 142 (7) 1431-1443
  • 91 Shen WJ, Dong R, Chen G, Zheng S. microRNA-222 modulates liver fibrosis in a murine model of biliary atresia. Biochem Biophys Res Commun 2014; 446 (1) 155-159
  • 92 Yamaura Y, Nakajima M, Takagi S, Fukami T, Tsuneyama K, Yokoi T. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS ONE 2012; 7 (2) e30250
  • 93 Woolbright BL, Antoine DJ, Jenkins RE, Bajt ML, Park BK, Jaeschke H. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol 2013; 273 (3) 524-531
  • 94 Ninomiya M, Kondo Y, Funayama R , et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS ONE 2013; 8 (6) e66086
  • 95 Qin B, Huang F, Liang Y, Yang Z, Zhong R. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2013; 28 (3) 543-550
  • 96 Katsushima F, Takahashi A, Sakamoto N, Kanno Y, Abe K, Ohira H. Expression of micro-RNAs in peripheral blood mononuclear cells from primary biliary cirrhosis patients. Hepatol Res 2014; 44 (10) E189-E197
  • 97 Zahm AM, Hand NJ, Boateng LA, Friedman JR. Circulating microRNA is a biomarker of biliary atresia. J Pediatr Gastroenterol Nutr 2012; 55 (4) 366-369
  • 98 O'Hara SP, Gradilone SA, Masyuk TV, Tabibian JH, LaRusso NF. MicroRNAs in cholangiopathies. Curr Pathobiol Rep 2014; 2 (3) 133-142
  • 99 Elfimova N, Schlattjan M, Sowa JP, Dienes HP, Canbay A, Odenthal M. Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis. Front Phys 2012; 3: 476
  • 100 Waidmann O, Köberle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS ONE 2012; 7 (9) e45652
  • 101 Chen YJ, Zhu JM, Wu H , et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PLoS ONE 2013; 8 (6) e66577
  • 102 Gehrau RC, Mas VR, Maluf DG. Hepatic disease biomarkers and liver transplantation: what is the potential utility of microRNAs?. Expert Rev Gastroenterol Hepatol 2013; 7 (2) 157-170